Introduction
. These drugs act as inhibitors of HIV-1 reverse transcriptase (RT) after phosphorylation to their corresponding 5′-triphosphates (TP) by cellular enzymes. Because of the rapid development of drug resistance when these nucleoside RT inhibitors (NRTIs) are used as a monotherapy, it is recommended that they are used in combination with non-nucleoside RT inhibitors (NNRTIs) and protease inhibitors (PIs) (Carpenter et al., 2000) . The use of such highly active antiretroviral therapy (HAART), has resulted in significant reductions in viral load, increased CD4 cell counts and prolonged survival for HIV-infected individuals (Hammer et al., 1997; Gulick et al., 1997; Autran et al., 1997; Palella et al., 1998) . Drug resistance however, particularly after long-term chemotherapy remains a major problem (Shafer et al., 1994; Shirasaka et al., 1995) . The number of mutations now identified as being associated with NRTI, NNRTI and PI drug resistance is substantial and knowledge of cross-resistance patterns are constantly being updated (Schinazi et al., 1999) . Because of this problem, the identification of selective new agents with activity against drug-resistant strains of HIV-1 and different patterns of cross-resistance is essential.
The heterosubstituted nucleoside analogue 2′-deoxy-3′-oxa-4′-thiocytidine (dOTC) is structurally related to 3TC (Coates et al., 1992a; , but has an inversion of oxygen and sulphur in the furanosyl ring. Unlike 3TC (L-sugar racemate only), the compound is a mix of two enantiomeric forms, (+)dOTC (BCH-10619) and (-)dOTC (BCH-10618), with L-sugar and D-sugar configurations, respectively (Figure 1 ). It has previously been reported that like 3TC (Coates et al., 1992b) , both enantiomers have activity against HIV-1 in T and monocyte cell lines as well as in cord blood mononuclear cells (Mansour et al., 1995a,b) . However, cytotoxicity studies have revealed that (-)dOTC has a slightly greater selectivity than (+)dOTC (Mansour et al., 1995b) . More recently, we have reported that the racemate maintains the more desirable features of the individual enantiomers with respect to potency and toxicity . Intracellular metabolism studies have shown that dOTC is phosphorylated via the deoxycytidine kinase pathway to the TP derivatives of its enantiomers, which had a half-life of 2-3 h, and were more potent at inhibiting HIV-1 RT in vitro than 3TC-TP. Furthermore, in vitro toxicity studies have indicated that dOTC was well tolerated in cell culture, and showed that dOTC-TP had good selectivity for HIV-1 RT compared with human DNA polymerases α, β and γ . When administered orally to rats, dOTC was well absorbed with a bioavailability of approximately 77%, with approximately 16.5% of the serum levels found in the cerebrospinal fluid. This compound showed no major side-effects in Phase I trials and is currently in Phase I/II efficacy studies in HIV-infected individuals.
Due to the structural similarity of dOTC and 3TC, a compound known to rapidly select for mutants with highlevel resistance (Wainberg et al., 1995) , it was considered important to investigate for cross-resistance to dOTC and its enantiomers. 3TC selects, both in cell culture and in vivo, for mutants with amino acid changes of methionine to either isoleucine or valine at codon 184 in the highly conserved YMDD motif of the RT, which confers >100-fold resistance (Boucher et al., 1993) . dOTC was investigated for activity against laboratory strains of HIV-1 with mutations at RT position 184, and against genotypically and phenotypically characterized clinical isolates with resistance to 3TC, or dual resistance to 3TC and AZT. In addition, the activity of dOTC against a limited number of other drug-resistant viruses, with defined mutations in the RT gene, were investigated in order to identify any cross-resistance with other RT inhibitors. We have investigated the rate of emergence of virus resistant to dOTC, compared to and in combination with 3TC and identified the associated mutations in the RT gene. Finally, the ultimate success of dOTC in the clinic will inevitably relate to its use in drug combination regimens. We have therefore investigated the effect of dOTC in two-way combinations with other compounds currently licensed for use in patients with AIDS. These drugs include the NRTIs AZT, 3TC, d4T and ddI, as well as the NNRTI nevirapine and the PIs saquinavir, ritonavir and indinavir.
Materials and Methods

Compounds
The cytosine nucleoside analogue dOTC, its enantiomers and 3TC were synthesized at Biochem Pharma Inc. as DL Taylor et al. 2 ©2000 International Medical Press described previously (Belleau et al., 1993; Mansour et al., 1995a,b) . AZT, d4T and ddI were purchased from the Sigma Chemical Co. (Poole, Dorset, UK) and indinavir and ritonavir were purchased from Moravek Biochemicals (Brea, Calif., USA). Saquinavir was provided by Roche Products Ltd, (Welwyn Garden City, UK) and nevirapine (BI-RG-587) by Boehringer Ingelheim Pharmaceuticals, Inc. (Ridgefield, Conn., USA). All compounds were prepared as 10 mM stocks in water or dimethylsulphoxide and were stored at -20°C. Stock solutions were diluted further in culture medium on the day of assay.
Virus and cells
MT-4 and C8166 T-cell lines and laboratory strains of HIV-1, as well as recombinant strains of the molecular clone HIV-1 HXB2 , were obtained through the MRC AIDS Directed Program Reagent Project (National Institute for Biological Standards and Control, South Mimms, UK). AZT-, 3TC-, PMEA-, nevirapine-and saquinavir-resistant strains of HIV-1 RF were obtained after culture of virus in the presence of increasing concentrations of compound as described previously (Taylor et al., 1996 (Taylor et al., , 1997 ) and the mutations determined by sequencing the RT or protease genes. T-cells were cultured in RPMI 1640 (Gibco BRL) supplemented with 10% fetal calf serum, and antibiotics. Human PBMCs were isolated by Lymphoprep (Nycomed Pharma As, Oslo, Norway), density gradient centrifugation from acid citrate dextrose (ACD)-treated buffy coat (National Blood Service, Colindale, London, UK), and depletion of CD8 cells using T cytotoxic/suppressor dyna beads according to the manufacturers instructions (Dyna, Oslo, Norway). The PBMCs were cultured in RPMI as described above, but also supplemented with 10 µg/ml phytohaemaglutinin (PHA) and 10 U/ml human recombinant interleukin 2 (IL-2) (Boehringer Mannheim) for 3 days prior to infection with HIV-1. Wild-type and drugresistant clinical isolates of HIV-1 were obtained after coculture of PBMCs from HIV-1-infected patients with PHA-stimulated PBMCs from blood donors. Clinical isolates were genotyped using the HIV-1 RT Line Probe Assay (LiPA HIV-1 RT) (Murex Innogenetics, Ghent, Belgium) after amplification of RT proviral DNA by nested PCR as described previously (Stuyver et al., 1997) .
Antiviral assays
C8166 T-cells were infected with wild-type or drug-resistant strains of HIV-1 at a multiplicity of infection (MOI) of 0.001 for 2 h at room temperature, washed and then distributed (1×10 5 cells per well) into 96-well cell culture plates containing different concentrations of test compound. After incubation at 37°C for 3 days, the cell-free culture fluid was assayed for levels of p24 viral antigen using the Murex HIV Antigen ELISA (Abbott). For assays using MT-4 cells, the MTT cell viability assay was used as described previously (Taylor et al., 1996) . For assays in PBMCs, 3-day PHA-and IL-2-stimulated cells were washed and infected with clinical isolates or laboratory strains of HIV-1 (virus input ranged from 50-5000 pg of p24 per 10 7 cells) for 2 h at room temperature. The cells were then washed and distributed at a concentration of 5×10 5 cells per well, into 48-well cell culture plates containing different concentrations of test compound and 10 U/ml IL-2. The plates were incubated for 7 days at 37°C and the cell-free culture fluid from duplicate wells were assayed for levels of p24 viral antigen as described above. Effective concentration values of 50 and 90% (EC 50 and EC 90 ) were determined after plotting dose-response curves.
Selection of drug-resistant virus and PCR sequencing
The wild-type HIV-1 strain RF was cultured in C8166 cells in the presence of different concentrations of dOTC, (-)dOTC and (+)dOTC and resistant virus selected as previously described for other drug-resistant variants (Taylor et al., 1996) . Mutants with resistance to 3TC were selected in parallel and the highest concentrations of compound used were 200 µM. Virus was screened for drug-sensitivity in MT-4 cells by MTT cell viability assay and the RT gene sequenced after 10, 15 and 20 passages. For sequencing, DNA was purified from drug-treated virus-infected cells and the RT gene amplified from proviral DNA as described previously (Taylor et al., 1996) . Sequencing was performed on two independently generated PCR amplifications using the primers described previously (Taylor et al., 1996) and the Big Dye terminator cycle sequencing ready reaction kit (Applied Biosystems, UK), according to the manufacturer's instructions. Samples were run on an Applied Biosystems ABI 310 and the sequence determined using Chromas and DNA Star software.
Drug combination assays
For two-way drug combination assays, chequerboards of different drug concentrations (serial half log dilutions and duplicate wells) were created in 48-well cell culture plates. HIV-1 RF -infected, washed PBMCs were then distributed into the wells, the plates incubated for 7 days and the cellfree culture fluid assayed for levels of p24 viral antigen, as described above. Three totally independent experiments were carried out for each two-way combination and the data analysed using the MacSynergy II program (Prichard & Shipman, 1990; Prichard et al., 1993) . The difference between the observed combined effects and those expected if the interactions had occurred independently are expressed as a synergy volume (square, micromolar, percent) above or below a plane that represents no interactive effects. Any peaks above the plane are indicative of synergy, whilst any peaks below the plane are indicative of antagonism. The confidence intervals around the experimental dose-response surface are used to evaluate the data statistically, and the volume of the peaks is calculated and used to quantify the volume of synergy produced. Values of synergy or antagonism <25 µM 2 % at 95% confidence should be regarded as insignificant. Values between 25 and 50 µM 2 %, however, are considered a minor but significant amount of synergy, volumes between 50 and 100 µM 2 % are indicative of moderate synergy and values >100 µM 2 % indicate strong synergy.
Results
Anti-HIV activity of dOTC, (-)dOTC and (+)dOTC against wild-type strains of HIV-1
Prior to investigating the antiviral activity of dOTC, (-)-dOTC and (+)-dOTC against drug-resistant strains of HIV-1, the activity against different wild-type laboratoryadapted and primary isolates was investigated in both T cell lines and in PBMCs. The treatment regimens of the individuals from whom the primary isolates were obtained was unknown, but they were unlikely to have been treated extensively with antiretrovirals due to the date of initial virus isolation (pre-1993) . Previous studies with these isolates had not indicated phenotypic resistance to any of the antiretroviral drugs investigated and no drug-resistance associated mutations were identified by PCR sequencing.
The results are shown in Table 1 and confirm (as reported by Mansour et al., 1995b ) that dOTC, (-)dOTC and (+)dOTC had equivalent anti-HIV-1 activity. EC 50 values for wild-type viruses in PBMCs were in the range 0.05-2.8 µM, and similar values were obtained for the HXB2 strain of HIV-1 in C8166 cells when antiviral activity was assessed by measuring reductions in levels of p24 viral antigen. It was evident that EC 50 values were approximately 10-fold higher when a cell viability assay was used for assessment of antiviral activity. In the T cell lines as well as in PBMCs, dOTC and its enantiomers were approximately 15-25-fold less active than 3TC.
Activity of dOTC, (-)dOTC and (+)dOTC against drug-resistant strains of HIV-1 dOTC and its two enantiomers were investigated for activity against recombinant strains of HIV-1 HXB2 with defined amino acid changes in the RT gene and resistance to AZT (67N, 70R, 215F, 219Q), 3TC (184V) or triple drug resistance to AZT, ddI and nevirapine (41L, 74V, 106A, 215Y ). For these studies C8166 T cells were infected with the appropriate strain of HIV-1 and the antiviral effect determined by measuring levels of extracellular p24 3 days post-infection. In addition, the compounds were investigated in the same way for activity against strains of HIV-1 RF selected after in vitro culture, with resistance to the RT inhibitors AZT (M41L), 3TC (184V and 184I), PMEA (K65R), nevirapine (106I, 188C) and the protease inhibitor saquinavir (48V, 90M) DL Taylor et al. Table 1 . Activity of dOTC, (-)dOTC and (+)dOTC against wild-type strains of HIV-1 (Table 2 ). The three compounds had similar activity against the wild-type strains as they did against the AZT-, nevirapine-, ddI-, PMEA-and saquinavir-resistant viruses (<3-fold change in EC 50 ). Against the HIV-1 RF (M184I/V) 3TC-resistant viruses, however, a shift in sensitivity was apparent for dOTC and both of its enantiomers. For the HIV-1 RF M184I mutant the shift in EC 50 was 4.7-, 5.5-and 5.0-fold for dOTC, (-)dOTC and (+)dOTC, respectively, compared with a 365-fold change seen with 3TC. For the HIV-1 RF M184V mutant the shift in EC 50 was 7.0-, 8.1-and >18-fold for dOTC, (-)dOTC and (+)dOTC, respectively, compared with a >3000-fold change seen with 3TC. This low-level cross-resistance to dOTC and its enantiomers was not apparent with the HIV-1 HXB2 M184V mutant even though this virus was 845-fold resistant to 3TC. As mentioned above, PMEAresistant virus with the K65R mutation showed no significant change in sensitivity to dOTC and its enantiomers, although this virus was 34-fold cross-resistant to 3TC. Virus with triple drug resistance to nevirapine (>100-fold), AZT (>20-fold) and ddI (fourfold) with amino acid changes 41L, 74V, 106A and 215Y was approximately fourfold less sensitive to dOTC and its enantiomers.
Anti-HIV activity of dOTC, (-)dOTC and (+)dOTC against clinical isolates of HIV-1 with phenotypic and genotypic resistance to 3TC and AZT
A total of 21 HIV-1 isolates were cultured from blood samples obtained from patients enrolled in the Quatro trial and treated for 32 or 64 weeks with 3TC and AZT. Some patients were also treated with ddC and the NNRTI loviride, but it was unknown at the time of isolation into which arm of the trial the patients were enrolled. These viruses were genotyped using the Murex LiPA HIV-1 RT after amplification of RT proviral DNA by PCR, according to the manufacturers instructions. This assay will identify amino acids present at specific positions in the RT known to be associated with resistance to nucleoside analogues (Stuyver et al., 1997) . Using this assay, the clinical isolates obtained were categorized as genotypically wild-type, resistant to 3TC (184V) or dually resistant to 3TC and AZT (184V and either 41L or 70R or 215Y/F). In a number of Antiviral Chemistry & Chemotherapy 11:4 5 *EC 50 values represent the results from single assays or in some cases triplicate assays ±SD and were determined in C8166 cells by measuring the reduction in levels of p24 viral antigen 3 days post-infection. †3TC-resistant virus (amino acid change in the RT: 184V). ‡AZT-resistant virus (amino acid changes in the RT: 67N, 70R, 215F, 219Q). §AZT/ddI/Nevirapine-resistant virus (amino acid changes in the RT: 41L, 74V, 106A, 215Y). ¶AZT-resistant virus (amino acid change in the RT:41L). **3TC-resistant virus (amino acid change in the RT: 184I). † †3TC-resistant virus (amino acid changes in the RT: 184V). ‡ ‡PMEA-resistant virus (amino acid change in the RT: 65R). § §saquinavir-resistant virus (amino acid change in the protease gene: 48V, 90M). ¶ ¶nevirapine-resistant virus (amino acid changes in the RT: 106I, 188C Table 2 . Activity of dOTC, (-)dOTC and (+)dOTC against drug-resistant strains of HIV-1 instances the amino acids present at certain positions were not identified, and the genotype was undefined with respect to AZT resistance, and in other instances it was apparent that there were mixed genotypes present (Table 3 ). The phenotypes of these viruses were determined in PBMCs by measuring the reduction in levels of p24 antigen in the culture fluid of infected cells treated with dOTC and its enantiomers, 3TC or AZT ( 
In vitro selection and characterization of HIV-1 resistant to dOTC, (-)dOTC and (+)dOTC
In order to determine whether virus resistant to dOTC and its enantiomers could be readily selected in vitro, HIV-1 RF was passaged in C8166 cells in the presence of increasing concentrations of each of the compounds, in parallel with 3TC. Virus growth was monitored by the formation of virus-induced syncytia and when it was apparent that resistant virus had been selected, the RT gene was amplified by PCR from proviral DNA and the PCR product directly sequenced to identify any mutations. The mutant viruses were also titrated and screened for sensitivity to each of the compounds, in parallel with wild-type virus in MT-4 cells, as well as PBMCs. Virus resistant to 3TC was selected relatively rapidly (after eight passages) in vitro as previously reported, and the methionine (ATG) at position 184 of the RT was changed to either isoleucine (ATA) or valine (GTA). Virus resistant to (+)dOTC was also selected relatively easily (after 10 passages) and had a methionine (ATG) to isoleucine (ATA) exchange at position 184 of the RT. In comparison, virus resistant to dOTC and (-)dOTC took longer to appear in vitro. After 10 passages in the presence of compound up to 200 µM, no genotypic or phenotypic changes were identified. However, after 15 passages for (-)dOTC and 20 passages for dOTC, drug-resistant virus was selected and the methionine (ATG) residue at 184 was found to have changed to a valine (GTG) in both instances. In addition, virus grown in the presence of dOTC had an amino acid change at position 65, where the lysine residue (AAA) had partially changed to an arginine (AGA).
The results of the phenotypic assays are shown in Table 4 and indicate that these mutant viruses showed low-level resistance (<10-fold change in EC 50 ) to dOTC and (-)dOTC, slightly greater resistance (>10-fold) to (+)dOTC, and high-level resistance to 3TC. These results were consistent with the data obtained with recombinant viruses and clinical isolates. When virus was grown in the presence of 3TC and dOTC in combination (1:10 molar ratio), the selection of drug-resistant virus was not prevented or delayed and sequencing revealed the characteristic 184 methionine to valine amino acid change (data not shown).
Drug combination studies
The effect of dOTC in two-way combination in vitro with the nucleoside RT inhibitors AZT, 3TC, d4T and ddI, the non-nucleoside RT inhibitor nevirapine and the protease inhibitors saquinavir, indinavir and ritonavir, was investigated. Assays were carried out in acutely infected PBMCs, and inhibition of viral replication determined by measuring the reduction in levels of p24 viral antigen in the culture supernatant. For each two-way combination, three totally independent experiments were carried out. The data from these experiments was analysed using the MacSynergy II program and 3D synergy plots constructed (Figure 2 ). At 95% confidence levels, the calculated synergistic volumes above the plane of independence were small in most experiments, ranging from 0 to 17.5 µM 2 %, indicative of additive interactions. In the case of 3TC and d4T, in combination with dOTC, the calculated volumes of synergy were 42.0 and 27.5 µM 2 % (95% confidence level), respectively, indicative of slightly synergistic interactions. No significant antagonism was recorded in any experiment, with values ranging from 0 to 11.0 µM 2 %. The same combination experiments were carried out in MT-4 cells using the MTT cell viability assay, and an additive interaction was recorded in all experiments when data was analysed using either the MacSynergy II program or by construction of isobolograms (results not shown).
Discussion
The data presented show that dOTC and its enantiomeric constituents exhibit good activity against genotypically and phenotypically characterized 'wild-type' clinical isolates of HIV-1 in PBMCs and laboratory strains in T cell lines. In general, the concentrations of compound required for inhibition of viral replication were consistent with previous reports Mansour et al., 1995a,b) . However, EC 50 values approximately 10-fold higher were obtained when cell viability assays, instead of p24 measurements, were used to determine antiviral activity. This is likely to be due to the higher MOI required for these cytopathicity assays. A similar shift in activity was recorded with 3TC. In addition, these heterosubstituted nucleoside analogues maintained good activity against AZT-, ddI-, nevirapine-, PMEA-and saquinavir-resistant recombinant and in vitro selected laboratory strains of HIV-1. The activity of dOTC and its enantiomers against a more comprehensive range of viral mutants, including virus with the Q151M multidrug resistance-associated mutation, have not yet been carried out, but will be the subject of future studies. It is unclear why in vitro selected 3TC-resistant viruses with M184V and M184I mutations, or 3TC-resistant clinical isolates, showed a degree of cross-resistance to dOTC and its enantiomers, whilst the infectious molecular clone HIV-1 HXB2 (with a M184V exchange introduced by site-directed mutagenesis) appeared to remain sensitive. These observations were reproducible and were also made by Richard et al. (1999) in their study. It is possible that either the drug-selected viruses contain additional mutations that have not been identified, or the genetic make-up of the HIV-1 HXB2 MIC is important. The M184V and M184I mutations are known to confer high-level resistance to 3TC (Boucher et al., 1993) and therefore some crossresistance was expected based on the structural similarity of 3TC and dOTC. The racemate and the (-) enantiomer, however, showed only low-level resistance compared with the (+) enantiomer, which showed a greater shift in sensitivity. This was consistent with a stereochemical rationale in that the triphosphate and cytosine moieties of (+)dOTC are orientated in a similar way as in the L-nucleoside analogue 3TC (Mansour et al., 1995a,b) . However, compared with the >100-fold shift in EC 50 seen with 3TC against viruses with M184I or M184V mutations, the shift with (+)dOTC was significantly less (five-to 30-fold). The results obtained with drug-resistant laboratory strains of HIV-1 were consistent with observations recorded with 3TC-and AZT-resistant primary isolates, in that a minor shift in mean EC 50 was recorded with dOTC and (-)dOTC (twofold) and a larger shift with (+)dOTC (eightfold). In relation to these observations, dOTC has recently been shown to have good inhibitory activity against 3TC-resistant as well as wild-type virus in the SCID-hu Thy/Liv mouse model of HIV infection (Stoddart et al., 2000) .
Experiments to select variants resistant to dOTC and its two enantiomers by continued passage of virus in cell culture in increasing concentrations of compound, indicated that virus resistant to (+)dOTC was selected relatively rapidly. As with 3TC, a codon change at position 184 in the highly conserved YMDD motif of RT was observed after sequencing. In contrast to 3TC, however, the increase in EC 50 for (+)dOTC was only around fivefold, compared with a 100-fold shift for 3TC. The selection of virus with resistance to the racemic compound and (-)dOTC took longer and the degree of resistance was relatively minor. These observations were consistent with those made by Richard et al. (1999) . With virus selected after growth in the presence of dOTC or (-)dOTC an amino acid change at RT position 184 was again identified. This was consistent with previous observations in which there was a minor shift in EC 50 when viruses harbouring these mutations were screened. In addition to the codon change at position 184, a partial change of lysine to arginine at position 65, after prolonged passage in the presence of dOTC, was also recorded. This K65R mutation has been observed previously in vitro and confers resistance to 3TC, ddC (Gu et al., 1994) , PMEA (Gu et al., 1995a; Taylor et al., 1996) and abacavir (Tisdale et al., 1997) . The 65R/184V double mutant has also been previously observed in a patient on ddC therapy (Gu et al., 1995b) . This virus with dual codon changes at positions 65 and 184 showed only low-level resistance to dOTC (<5-fold). It is evident from studies with 3TC that the presence of the 184 change is advantageous with respect to retaining viral sensitivity to AZT, even in the presence of AZT resistance mutations (Larder et al., 1995) , and it is also reported to be less replication-
